Company points to substantial cost and resource savings for hospitals, highlighted in new study
Non-inferiority to Balloon Kyphoplasty in osteoporotic vertebral compression fractures despite statistically significant risk factors favoring the BKP control group.
Benvenue Medical has chosen the Society for Interventional Radiology Annual Scientific Meeting at which to announce the full commercial launch of its system, supported by further favourable clinical data.
Benvenue is trumpeting results of an independent, prospective, randomized study which found that the company’s Kiva® VCF Treatment System was as effective as Balloon Kyphoplasty in reducing pain associated with osteolytic vertebral body metastases.
The George Washington University Hospital has become the first in the country to treat VCF patients with Benvenue Medical’s Kiva Vertebral Compression Fracture (VCF) Treatment System following its January FDA clearance.
The Kiva® VCF Treatment System by Benvenue Medical, Inc. has received U.S. FDA 510(k) clearance for the reduction and treatment of spinal fractures. The company says its implant based system is the first departure from balloon kyphoplasty for a decade.
First randomized controlled study comparing Benvenue’s Kiva VCF treatment system to Medtronic’s Kyphon Balloon Kyphoplasty concludes ahead of schedule – Pre-defined criteria for early Stopping of subject enrollment met.
Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has received CE Mark approval in Europe for the Kiva™ Vertebral Compression Fracture (VCF) Treatment System.
New money should keep foot on accelerator with commercialisation efforts of new spinal technologies
Benvenue Medical has gained U.S. FDA 510(k) clearance for its Luna® 360 Interbody Fusion System for spinal fusion treatment of symptomatic degenerative disc disease
Benvenue Medical, Inc. has closed out a $64 million funding round that it says will help it build its US commercial presence and generally support its growth objectives in the degenerative disc and vertebral compression fracture markets.
Regentis Biomaterials says new clinical data demonstrates the efficacy and safety of its GelrinC implant for treating articular cartilage in injured knees. At the ICRS World Congress in Izmir, Turkey, the clinical results demonstrated sustained knee function improvement over 24 months after implantation and significant pain reduction.
Expanding Orthopedics Inc. has passed the 1,000th XPED Expanding Pedicle Screw™ milestone at the prestigious and historical Rizzoli Institute in Bologna, Italy. The device, is a uniquely expandable pedicle screw designed to offer enhanced anchoring in compromised bone.